Long term response on Regorafenib in non-V600E BRAF mutated colon cancer: a case report

BMC Cancer. 2019 Jun 11;19(1):567. doi: 10.1186/s12885-019-5763-5.


Background: Non-V600E BRAF mutated colorectal cancer (CRC) is a rare disease entity with specific clinical features. These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation. Notably, median overall survival is longer than in wild-type BRAF CRC. Little is known about treatment possibilities in these patients.

Case presentation: We present the case of a 59 year old patient with a rare mutation in BRAF codon 594, who progressed rapidly on all classical therapies but experienced a clear and long lasting response on treatment with Regorafenib.

Conclusion: Little is known about therapies that can be effective in the rare non-V600E BRAF mutated CRCs. We present a patient who had a definite response to treatment with Regorafenib. There are no predictive markers that define a subset of CRC patients who benefit most from Regorafenib. The specific features of this non-V600E BRAF mutated CRC may be relevant in the exploration of predictive biomarkers for the efficacy of Regorafenib.

Keywords: Case report; Colon cancer; Epithelial to mesenchymal transition; Non-V600E BRAF mutation; Regorafenib.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / secondary
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Bevacizumab / therapeutic use
  • Biomarkers, Tumor / genetics
  • Carcinoembryonic Antigen / blood
  • Cetuximab / therapeutic use
  • Colonic Neoplasms / drug therapy*
  • Colonic Neoplasms / pathology
  • Colonic Neoplasms / radiotherapy
  • Colonic Neoplasms / surgery
  • Exons / genetics
  • Fluorouracil / therapeutic use
  • Follow-Up Studies
  • Humans
  • Leucovorin / therapeutic use
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / secondary
  • Male
  • Middle Aged
  • Mutation*
  • Organoplatinum Compounds / therapeutic use
  • Phenylurea Compounds / administration & dosage
  • Phenylurea Compounds / therapeutic use*
  • Proto-Oncogene Proteins B-raf / genetics*
  • Pyridines / administration & dosage
  • Pyridines / therapeutic use*
  • Tomography, X-Ray Computed
  • Treatment Outcome


  • Antineoplastic Agents
  • Biomarkers, Tumor
  • Carcinoembryonic Antigen
  • Organoplatinum Compounds
  • Phenylurea Compounds
  • Pyridines
  • regorafenib
  • Bevacizumab
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf
  • Cetuximab
  • Leucovorin
  • Fluorouracil

Supplementary concepts

  • Folfox protocol